In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Dr. Bijal Shah explores the recent advancements and shifts in treatment strategies for Ph+ ALL, driven by innovations in targeted therapies and evolving clinical practices ...

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and ...

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, ...

Top articles about HIV this year included effects of HIV on tooth loss and cardiac surgery, caregiver experiences, and a ...

Markey Cancer Center combats clinical trial misconceptions by emphasizing standard care and changing terminology to improve ...